Hsbc Holdings PLC acquired a new position in shares of Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 9,598 shares of the company's stock, valued at approximately $3,653,000.
Several other large investors also recently made changes to their positions in KRYS. Silvant Capital Management LLC purchased a new position in shares of Krystal Biotech in the 2nd quarter valued at $30,000. Western Wealth Management LLC purchased a new stake in Krystal Biotech during the 1st quarter worth $34,000. Greenline Wealth Management LLC purchased a new stake in Krystal Biotech during the 4th quarter worth $34,000. UMB Bank n.a. increased its holdings in Krystal Biotech by 34.6% in the 4th quarter. UMB Bank n.a. now owns 144 shares of the company's stock valued at $36,000 after purchasing an additional 37 shares in the last quarter. Finally, Global Retirement Partners LLC increased its holdings in Krystal Biotech by 788.9% in the 4th quarter. Global Retirement Partners LLC now owns 160 shares of the company's stock valued at $39,000 after purchasing an additional 142 shares in the last quarter. Institutional investors and hedge funds own 86.29% of the company's stock.
Krystal Biotech Price Performance
NASDAQ:KRYS opened at $351.46 on Friday. The firm has a 50-day moving average of $348.64 and a two-hundred day moving average of $304.16. The stock has a market cap of $10.40 billion, a P/E ratio of 44.04 and a beta of 0.53. Krystal Biotech, Inc. has a 1-year low of $136.73 and a 1-year high of $382.54.
Krystal Biotech (NASDAQ:KRYS - Get Free Report) last released its quarterly earnings results on Monday, August 3rd. The company reported $1.79 EPS for the quarter, topping the consensus estimate of $1.70 by $0.09. The business had revenue of $119.22 million for the quarter, compared to analysts' expectations of $120.93 million. Krystal Biotech had a return on equity of 19.34% and a net margin of 54.82%. As a group, equities analysts expect that Krystal Biotech, Inc. will post 7.48 earnings per share for the current year.
Analyst Upgrades and Downgrades
A number of research analysts have commented on the company. Chardan Capital upgraded Krystal Biotech to a "strong-buy" rating in a research note on Monday, August 3rd. Wall Street Zen lowered Krystal Biotech from a "buy" rating to a "hold" rating in a research note on Saturday, June 20th. HC Wainwright raised their target price on Krystal Biotech from $310.00 to $361.00 and gave the company a "buy" rating in a report on Tuesday, June 16th. Bank of America boosted their price target on Krystal Biotech from $364.00 to $396.00 and gave the stock a "buy" rating in a research report on Tuesday, July 14th. Finally, TD Cowen upped their price target on Krystal Biotech from $306.00 to $403.00 and gave the stock a "buy" rating in a report on Thursday, June 18th. One equities research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating and two have issued a Hold rating to the company's stock. Based on data from MarketBeat, Krystal Biotech currently has a consensus rating of "Moderate Buy" and an average target price of $365.40.
Check Out Our Latest Report on Krystal Biotech
Insiders Place Their Bets
In other news, Director Dino A. Rossi sold 25,000 shares of the stock in a transaction that occurred on Friday, August 14th. The stock was sold at an average price of $329.12, for a total transaction of $8,228,000.00. Following the completion of the transaction, the director directly owned 50,000 shares in the company, valued at approximately $16,456,000. This represents a 33.33% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, EVP John Charles Thomas sold 1,000 shares of the company's stock in a transaction on Thursday, June 25th. The shares were sold at an average price of $347.27, for a total transaction of $347,270.00. Following the completion of the sale, the executive vice president directly owned 1,000 shares in the company, valued at $347,270. This represents a 50.00% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 51,000 shares of company stock worth $16,278,020 in the last three months. 13.10% of the stock is owned by insiders.
About Krystal Biotech
(
Free Report)
Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.
The company's lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Krystal Biotech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Krystal Biotech wasn't on the list.
While Krystal Biotech currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.
This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
